Drug Trial News

RSS

Worldwide study to examine new treatments for IgA nephropathy

A patient from Birmingham is the first person to be recruited into a new worldwide study to test new treatments for a potentially life-threatening kidney condition called IgA nephropathy.

28 Jun 2018

AAA doses first patients in two clinical studies with PSMA-R2 for prostate cancer

Advanced Accelerator Applications S.A., a Novartis company and leader in nuclear medicine theragnostics, today announced that the first patients have been dosed in two Phase I/II clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane Antigen, which is commonly expressed on prostate cancer cells.

22 Jun 2018

New study is testing safety and efficacy of glycoside in breaking up kidney stones

For anyone who has suffered from kidney stones, the painful condition is not easily treatable, and patients are typically prescribed strong pain medication and fluids to alleviate symptoms.

20 Jun 2018

New guidance on selection and evaluation of wearable devices for use in regulatory clinical trials

Value in Health, the official journal of ISPOR (the professional society for health economics and outcomes research), announced today the publication of new guidance regarding the selection and evaluation of wearable devices for use in regulatory trials and to support labeling claims.

19 Jun 2018

Clinical trial targets metastatic colorectal cancer with new combination therapy

Rutgers Cancer Institute of New Jersey is offering a clinical trial targeting an advanced form of colorectal cancer with a combination vaccine/immunotherapy drug treatment.

19 Jun 2018

SetPoint announces positive long-term results of bioelectronic medicine to treat rheumatoid arthritis

SetPoint Medical, a clinical-stage biomedical technology company developing bioelectronic therapy for chronic inflammatory diseases, announced positive long-term data for its first-in-human study using bioelectronic medicine for rheumatoid arthritis

19 Jun 2018

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.

19 Jun 2018

New clinical trial finds no evidence to support use of tamsulosin for kidney stones

The latest research into finding medications to aid the passage of ureteral or kidney stones has shown that tamsulosin is not effective for patients across the board.

18 Jun 2018

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis

The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology, 2018, demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis with no severe or serious adverse events.

18 Jun 2018

Canakinumab reduces gout rate by more than half in atherosclerosis patients, study shows

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level.

18 Jun 2018

NIAID launches clinical trial of investigational RSV vaccine

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched a clinical trial of an investigational vaccine designed to protect against respiratory syncytial virus.

14 Jun 2018

Topical gel may lower breast cancer risk in women with dense breast tissue

Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast cancer.

14 Jun 2018

New clinical trial of MS drug will be first to recognize needs of wheelchair users

A new clinical trial testing a disease-modifying drug for multiple sclerosis will be the first in the world to recognise the importance of wheelchair users retaining the use of their hands.

14 Jun 2018

Metric-based virtual reality simulation improves training for physicians in mechanical thrombectomy

Mentice welcomes the publication of a research paper in the journal "Stroke" based on the use of its VIST® physics-based, high-fidelity simulator to train interventional neuroradiologists.

11 Jun 2018

EMA grants PRIME designation to Themis' chikungunya vaccine candidate

Themis announced today that the European Medicines Agency has granted PRIority MEdicines designation to its most advanced program in development, a vaccine to prevent chikungunya fever.

11 Jun 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

Esophageal cancer risk could be reduced by esomeprazole and low dose aspirin

According to the results of a phase III trial presented at the 2018 ASCO Annual Meeting, two simple over-the-counter medicines – high dose esomeprazole and low dose aspirin when taken regularly can moderately lessen the risk of high grade esophageal cancer in patients who are diagnosed with Barrett’s esophagus when taken for at least 7 years.

5 Jun 2018

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced preliminary results from its ongoing Phase I study of small activating RNA candidate MTL-CEBPA in advanced liver cancer.

4 Jun 2018

Protein inhibitor drug found to be safe and effective in treating patients with acute myeloid leukemia

Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia with relapsed or refractory disease.

4 Jun 2018

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the "stemness" of chronic leukemia cancer cells - their ability to self-renew and resist terminal differentiation and senescence.

1 Jun 2018

Drug Trial News

Worldwide study to examine new treatments for IgA nephropathy

AAA doses first patients in two clinical studies with PSMA-R2 for prostate cancer

New study is testing safety and efficacy of glycoside in breaking up kidney stones

New guidance on selection and evaluation of wearable devices for use in regulatory clinical trials

Clinical trial targets metastatic colorectal cancer with new combination therapy

SetPoint announces positive long-term results of bioelectronic medicine to treat rheumatoid arthritis

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

New clinical trial finds no evidence to support use of tamsulosin for kidney stones

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis

Canakinumab reduces gout rate by more than half in atherosclerosis patients, study shows

NIAID launches clinical trial of investigational RSV vaccine

Topical gel may lower breast cancer risk in women with dense breast tissue

New clinical trial of MS drug will be first to recognize needs of wheelchair users

Metric-based virtual reality simulation improves training for physicians in mechanical thrombectomy

EMA grants PRIME designation to Themis' chikungunya vaccine candidate

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Esophageal cancer risk could be reduced by esomeprazole and low dose aspirin

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

Protein inhibitor drug found to be safe and effective in treating patients with acute myeloid leukemia

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News